Turns a proven pill ingredient called roflumilast into prescription skin creams and foams that no competitor is legally allowed to make.
What this company is and how it runs — written from structure, not news.
Arcutis Biotherapeutics holds an exclusive licence from AstraZeneca to reformulate roflumilast — a molecule AstraZeneca originally developed as an oral lung drug — into topical creams and foams for skin conditions, and the licence contractually bars AstraZeneca itself from building competing versions. Because roflumilast is already proven safe in its oral form, each new skin condition Arcutis targets just needs its own clinical trial and FDA application rather than a new molecule, so every approval — plaque psoriasis, atopic dermatitis, seborrheic dermatitis — adds a prescribable product running through the same manufacturing and distribution infrastructure already in place. The catch is that no amount of money or factory capacity speeds up the regulatory sequence, which means the pipeline can only advance one approval at a time per indication, and the whole business — every approved product and every trial in progress — sits on a single licensed molecule. If AstraZeneca were ever to terminate that licence, Arcutis would lose its active ingredient across every product simultaneously, and the only internal backup compound, ARQ-234, has not demonstrated efficacy in any completed trial.
How does this company make money?
The company earns revenue each time a prescription for ZORYVE cream or foam is filled through a specialty pharmacy or sold directly to a hospital. How much money it actually collects depends heavily on what insurance plans agree to cover and what copay level patients face, both of which vary by approved indication and patient age group.
What makes this company hard to replace?
When a dermatologist moves a patient from ZORYVE foam to a different product, the patient has to learn a new way to apply the treatment — foam formulations require different skin preparation and coverage methods than creams or ointments. On top of that, insurance companies typically require a prior authorisation review before approving a switch, a process that takes two to four weeks, during which the patient's skin condition may worsen.
What limits this company?
Every new skin condition or patient group the company wants to treat requires its own Phase 2 trial, then a Phase 3 trial, then an FDA review that takes 12 to 18 months after the application is filed. No amount of money or factory capacity can skip or shorten that sequence. The pipeline can only move one approval at a time per condition.
What does this company depend on?
The company cannot run without a steady supply of the roflumilast active ingredient. It also depends on contract manufacturers that hold FDA approval to produce topical cream and foam to pharmaceutical quality standards. A dermatology-focused sales force with access to hospital and specialty clinic prescribers is essential to getting ZORYVE written on prescriptions. And for each new skin condition or age group, a fresh FDA approval is required before the product can be sold.
Who depends on this company?
Dermatologists who treat patients whose psoriasis or atopic dermatitis has not responded to steroid creams would lose the only FDA-approved topical phosphodiesterase-4 inhibitor available and would have to fall back on topical steroids or drugs taken by mouth. Pediatric patients with atopic dermatitis would lose the only non-steroidal topical treatment approved for their age group, and the alternatives carry greater risk of the drug entering the bloodstream.
How does this company scale?
The physical production of ZORYVE cream and foam can grow by adding contract manufacturing capacity and automated filling lines — that part scales relatively cheaply. What does not scale is the clinical and regulatory pipeline. Each new skin condition or age group still needs its own multi-year trial sequence and its own FDA application, no matter how large the manufacturing operation becomes.
What external forces can significantly affect this company?
Medicare Part D and commercial insurance plans decide how much patients pay out of pocket for ZORYVE, which directly affects how many prescriptions are filled. In Europe, the fact that the oral form of roflumilast is already approved for lung disease does not carry over — the company must go through the European Medicines Agency separately for each skin indication. The foam formulation also requires climate-controlled shipping and storage to stay stable, adding logistical complexity and cost to distribution.
Where is this company structurally vulnerable?
If the licensing agreement with AstraZeneca were cancelled, every approved ZORYVE product and every treatment the company is developing would instantly lose its active ingredient at the same moment. There is no alternative supplier for roflumilast, because the same contract that blocks AstraZeneca from competing also blocks anyone else from stepping in. The company's only backup molecule, ARQ-234, has not proven it works in any completed trial.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph